Blockchain Registration Transaction Record

Lantern Pharma Secures $4M in Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announces a $4 million registered direct offering and concurrent private placement to advance its AI-driven oncology pipeline. Read more.

This funding provides Lantern Pharma with additional capital to advance its AI-driven oncology pipeline, which includes promising candidates like LP-184 and LP-300. The involvement of Rodman & Renshaw and the concurrent private placement structure demonstrate investor confidence in the company's RADR platform, potentially accelerating the development of precision cancer therapies and creating value for shareholders. As the biotech sector increasingly embraces AI for drug discovery, Lantern's progress could signal broader industry trends and offer new hope for patients with hard-to-treat cancers.